MedPath

A combination immunotherapy for the patients with advanced or metastatic solid cancer

Phase 1
Conditions
solid cancer
Registration Number
JPRN-UMIN000020440
Lead Sponsor
Yamaguchi university Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
17
Inclusion Criteria

Not provided

Exclusion Criteria

Uncontroled general complication. etc

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety
Secondary Outcome Measures
NameTimeMethod
1)specific CTL response 2)overall survival 3)progression-free survival 4)Response rate 5)disease control rate
© Copyright 2025. All Rights Reserved by MedPath